Reata Pharmaceuticals (RETA) Files $80M Common Stock IPO

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ) filed a registration with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $80 million. The company plans to list on the Nasdaq under the symbol, "RETA."

Underwriters are Citigroup, Cowen and Company, and Piper Jaffray.

Reata is a clinical stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

The company continued, Our lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules called antioxidant inflammation modulators, or AIMs. Bardoxolone methyl is in Phase 2 clinical development for the treatment of pulmonary arterial hypertension, or PAH, and pulmonary hypertension due to interstitial lung disease, or PH-ILD, each of which are subsets of pulmonary hypertension, or PH. Initial data for PAH patients in our Phase 2 trial have been presented publicly at the CHEST meeting in October 2015. In addition, we have completed an interaction with the U.S. Food and Drug Administration, or FDA, on this initial data, and the FDA has concurred with our plan to initiate a Phase 3 trial in patients with PAH associated with connective tissue disease, or CTD-PAH. We plan to initiate this Phase 3 trial in the second half of 2016. RTA 408 is in Phase 2 clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, or FA, and mitochondrial myopathies, or MM. Beyond our lead product candidates, we have several promising preclinical programs. We believe that our product candidates and preclinical programs have the potential to improve clinical outcomes in numerous underserved patient populations.

You May Also Be Interested In

• YY Group Holding (YYGH) Closes $5M IPO
• GXO Logistics, Inc. (GXO) Launches Notes Offering
• Scilex Holding (SCLX) Prices 15M Share Offering at $1/sh